| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hemolysis | D006461 | 131 associated lipids |
| Tuberculosis | D014376 | 20 associated lipids |
| Stomach Ulcer | D013276 | 75 associated lipids |
| Nocardia Infections | D009617 | 6 associated lipids |
| Diarrhea | D003967 | 32 associated lipids |
| Hearing Loss, Sensorineural | D006319 | 8 associated lipids |
| Otitis Media | D010033 | 12 associated lipids |
| Carcinoma, Basal Cell | D002280 | 6 associated lipids |
| Arrhythmias, Cardiac | D001145 | 42 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| pmid: | ||||
| Dubé MP et al. | Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. California Collaborative Treatment Group. | 1999 | Clin. Infect. Dis. | pmid:10028084 |
| Goh KL et al. | Optimal treatment for duodenal ulcer disease: a cost-decision analysis in Malaysian patients. | 1999 | J. Gastroenterol. Hepatol. | pmid:10029275 |
| Horgen L et al. | Postantibiotic effects of rifampin, amikacin, clarithromycin and ethambutol used alone or in various two-, three- and four-drug combinations against Mycobacterium avium. | 1999 | FEMS Immunol. Med. Microbiol. | pmid:10030545 |
| Sakurai K et al. | [Importance of drug selection and the use of sensitivity tests for the eradication therapy for Helicobacter pylori]. | 1999 | Nippon Rinsho | pmid:10036938 |
| Fukazawa K et al. | [Antimicrobial resistance testing of H. pylori epsilometer test and disk diffusion test]. | 1999 | Nippon Rinsho | pmid:10036939 |
| Murakami K and Kimoto M | [Antibiotic-resistant H. pylori strains in the last ten years in Japan]. | 1999 | Nippon Rinsho | pmid:10036940 |
| Maeda S and Yoshida H | [Detection of Helicobacter pylori 23S rRNA gene mutation associated with clarithromycin resistance and its clinical applicability]. | 1999 | Nippon Rinsho | pmid:10036941 |
| Sekine H et al. | [Recurrence rate of H. pylori after successful eradication and second eradication therapy after initial failure of treatment]. | 1999 | Nippon Rinsho | pmid:10036947 |
| Iwasaki A | [Eradication rate and side effect from a point of view of Helicobacter pylori eradication of peptic ulcer disease in dual therapy or new triple therapy]. | 1999 | Nippon Rinsho | pmid:10036949 |
| Habu Y et al. | [Evaluation of the efficacy and the cost-effectiveness of proton pump inhibitor-based dual and triple therapy regimens for H. pylori eradication in peptic ulcer disease]. | 1999 | Nippon Rinsho | pmid:10036950 |
| Shirai T et al. | [Four kinds of new triple therapy regiments for Helicobacter pylori eradication in patients with peptic ulcer]. | 1999 | Nippon Rinsho | pmid:10036951 |
| Nakagawa M et al. | [A comparative study; one week treatment versus two weeks treatment with lansoprazol, amoxycillin and clarythromycin for the eradication of Helicobacter pylori in patient with gastric and duodenal ulcer]. | 1999 | Nippon Rinsho | pmid:10036952 |
| Kihira K et al. | [Triple therapy regimens involving H2 blockaders for therapy of Helicobacter pylori infections]. | 1999 | Nippon Rinsho | pmid:10036953 |
| Goto T et al. | [Erosive duodenitis after eradication therapy for Helicobacter pylori]. | 1999 | Nihon Shokakibyo Gakkai Zasshi | pmid:10047687 |
| Wang G et al. | Multiplex sequence analysis demonstrates the competitive growth advantage of the A-to-G mutants of clarithromycin-resistant Helicobacter pylori. | 1999 | Antimicrob. Agents Chemother. | pmid:10049289 |
| Woo PC et al. | Clarithromycin attenuates the inflammatory response induced by surgical trauma in a guinea pig model. | 1999 | Pharmacol. Res. | pmid:10051377 |
| Kistler A et al. | Therapeutic dilemma: crescentic mesangiocapillary glomerulonephritis type 1 in a patient on antituberculous therapy with rifampicin. | 1999 | Nephrol. Dial. Transplant. | pmid:10052525 |
| Yan JJ et al. | Disseminated Mycobacterium genavense infection in a patient with acquired immunodeficiency syndrome: first case report in Taiwan. | 1999 | J. Formos. Med. Assoc. | pmid:10063276 |
| Keto Y et al. | Healing of Helicobacter pylori-induced gastric ulcers in Mongolian gerbils: combined treatment with omeprazole and clarithromycin. | 1999 | Dig. Dis. Sci. | pmid:10063909 |
| Nilsson F and Walder M | [Antibiotic resistance of Helicobacter pylori in Malmö. Therapeutic success in spite of antibiotic resistance]. | 1999 | Lakartidningen | pmid:10064930 |
| Sato K and Tomioka H | [In vitro antimicrobial activities of quinolones, rifamycins and macrolides against Mycobacterium tuberculosis and M.avium complex: attempt to establish new assay methods which accurately reflect therapeutic effects of test agents in vivo]. | 1999 | Kekkaku | pmid:10067057 |
| Schultz-Süchting F et al. | Treatment of Helicobacter heilmannii-associated gastritis in a 14-year-old boy. | 1999 | J. Pediatr. Gastroenterol. Nutr. | pmid:10067743 |
| Vásconez C et al. | Helicobacter pylori, hyperammonemia and subclinical portosystemic encephalopathy: effects of eradication. | 1999 | J. Hepatol. | pmid:10068106 |
| Dehesa M et al. | [Comparison of 2 schedules based on pantoprazole for eradication of Helicobacter pylori in patients with active duodenal ulcer]. | 1998 Apr-Jun | Rev Gastroenterol Mex | pmid:10068730 |
| Yajima T et al. | Optimum spray congealing conditions for masking the bitter taste of clarithromycin in wax matrix. | 1999 | Chem. Pharm. Bull. | pmid:10071855 |
| Owen RJ | Helicobacter pylori resists arrest. | 1999 | Gut | pmid:10075942 |
| Marais A et al. | Direct detection of Helicobacter pylori resistance to macrolides by a polymerase chain reaction/DNA enzyme immunoassay in gastric biopsy specimens. | 1999 | Gut | pmid:10075951 |
| Shirtliff ME et al. | Oral rifampin plus azithromycin or clarithromycin to treat osteomyelitis in rabbits. | 1999 | Clin. Orthop. Relat. Res. | pmid:10078148 |
| Periti P and Mazzei T | Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen. | 1999 | J Chemother | pmid:10078776 |
| de Jong JJ et al. | Atypical mycobacterium infection with dermatological manifestation in a renal transplant recipient. | 1999 | Transpl. Int. | pmid:10080410 |
| Woo MS et al. | Pediatric transplant grand rounds. A case presentation: skin lesions in a post-lung transplant patient. | 1997 | Pediatr Transplant | pmid:10084776 |
| Moreau P et al. | Lack of efficacy of clarithromycin in advanced multiple myeloma. Intergroupe Français du Myélome (IFM) | 1999 | Leukemia | pmid:10086745 |
| Unge P | Antibiotic treatment of Helicobacter pylori infection. | 1999 | Curr. Top. Microbiol. Immunol. | pmid:10087665 |
| Wreiber K et al. | [Development of resistant Helicobacter pylori in Sweden. Tendency toward increasing resistance to clarithromycin]. | 1999 | Lakartidningen | pmid:10087796 |
| Sakatani M | [Multi-drug resistant mycobacterial infection]. | 1999 | Ryoikibetsu Shokogun Shirizu | pmid:10088372 |
| GarcÃa-Romero E et al. | [Treatment with omeprazole, clarithromycin and amoxicillin over 6 days in patients with Helicobacter pylori-infected duodenal ulcer]. | 1999 | Gastroenterol Hepatol | pmid:10089703 |
| Ramirez J et al. | Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. | 1999 | Clin Ther | pmid:10090428 |
| Ong EL | Prophylaxis against disseminated Mycobacterium avium complex in AIDS. | 1999 | J. Infect. | pmid:10090497 |
| Sunazuka T et al. | Effects of erythromycin and its derivatives on interleukin-8 release by human bronchial epithelial cell line BEAS-2B cells. | 1999 | J. Antibiot. | pmid:10092202 |
| Talley NJ et al. | Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. | 1999 | BMJ | pmid:10092259 |
| Khoo KH et al. | Altered expression profile of the surface glycopeptidolipids in drug-resistant clinical isolates of Mycobacterium avium complex. | 1999 | J. Biol. Chem. | pmid:10092667 |
| Torgano G et al. | Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease. | 1999 | Circulation | pmid:10096930 |
| Navuluri R and Yue S | Understanding peptic ulcer disease pharmacotherapeutics. | 1999 | Nurse Pract | pmid:10100245 |
| Tirén U et al. | Helicobacter pylori gastritis in children: efficacy of 2 weeks of treatment with clarithromycin, amoxicillin and omeprazole. | 1999 | Acta Paediatr. | pmid:10102149 |
| Graham DY et al. | Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102946 |
| Zanten SJ et al. | The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102960 |
| Van der Wouden EJ et al. | The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102961 |
| Wong BC et al. | Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102962 |
| Xiao SD et al. | High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102963 |